Catalyst Pharmaceuticals, Inc. – Lambert-Eaton Myasthenic Syndrome

Submitted By:

Published Date:

January 25, 2020

The primary objective of the study is:

• To provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate
therapy until the product becomes commercially available.

The secondary objective of the study is:

• To assess the long-term safety of amifampridine phosphate in patients with
LEMS/CMS/downbeat nystagmus

Rare Disease:

Lambert-Eaton Myasthenic Syndrome